{"doi":"10.1084/jem.20211546","title":"Tumor-derived OBP2A promotes prostate cancer castration resistance","abstract":"Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors in remission is almost completely ignored. Here, we report that odorant-binding protein (OBP2A) released from tumors in remission during ADT catches survival factors, such as CXCL15/IL8, to promote PCa cell androgen-independent growth and enhance the infiltration of myeloid-derived suppressor cells (MDSCs) into tumor microenvironment, leading to the emergence of castration resistance. OBP2A knockdown significantly inhibits CRPC and metastatic CRPC development and improves therapeutic efficacy of CTLA-4/PD-1 antibodies. Treatment with OBP2A-binding ligand α-pinene interrupts the function of OBP2A and suppresses CRPC development. Furthermore, α-pinene-conjugated doxorubicin/docetaxel can be specifically delivered to tumors, resulting in improved anticancer efficacy. Thus, our studies establish a novel concept for the emergence of PCa castration resistance and provide new therapeutic strategies for advanced PCa.","journal":"The Journal of Experimental Medicine","year":2022,"id":253976,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.953,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":900486,"name":"Shangwei Zhong","orcid":"0000-0002-8587-6452","position":1,"is_corresponding":false},{"id":660063,"name":"Fuzhuo Li","orcid":"0000-0002-2710-7743","position":2,"is_corresponding":false},{"id":900487,"name":"Changhao Huang","orcid":"0000-0003-1177-4290","position":3,"is_corresponding":false},{"id":900488,"name":"Xueyan Chen","orcid":"0000-0003-0193-1053","position":4,"is_corresponding":false},{"id":900489,"name":"Qingqing Liu","orcid":"0000-0001-6942-677X","position":5,"is_corresponding":false},{"id":559552,"name":"Shoujiao Peng","orcid":"0000-0003-3086-8372","position":6,"is_corresponding":false},{"id":475417,"name":"HaJeung Park","orcid":"0000-0003-4898-7919","position":7,"is_corresponding":false},{"id":900490,"name":"You Mie Lee","orcid":"0000-0002-5756-7169","position":8,"is_corresponding":false},{"id":635263,"name":"Jasreman Dhillon","orcid":"0000-0001-6785-3487","position":9,"is_corresponding":false},{"id":900491,"name":"Jun‐Li Luo","orcid":"0000-0002-7625-4766","position":10,"is_corresponding":false},{"id":900485,"name":"Ji-Hak Jeong","orcid":"0000-0001-9637-5461","position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T00:25:03.918844Z","pmid":"36547668","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}